15 results on '"Gopaluni, Seerapani"'
Search Results
2. Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models
3. 013. PERCUTANEOUS LYMPH NODE BIOPSY TO EXPLORE IMMUNE DYSREGULATION IN VASCULITIS: A PILOT PROJECT
4. 029. PR3-ANCA STATUS FOLLOWING RITUXIMAB: A USEFUL BIOMARKER FOR RELAPSE PREDICTION IN ANCA-ASSOCIATED VASCULITIS
5. 356. RITUXIMAB ASSOCIATED HYPOGAMMAGLOBULINAEMIA IN AUTOIMMUNE DISEASE: LONG TERM OUTCOMES
6. 247. CHARACTERISTICS, OUTCOMES AND PROGNOSTIC FACTORS OF PATIENTS WITH ACUTE MANIFESTATION OF SMALL VESSEL VASCULITIS ADMITTED TO INTENSIVE CARE: AN 18-YEAR SINGLE-CENTRE EXPERIENCE
7. 322. A RANDOMISED, DOUBLE-BLIND, CONTROLLED, MECHANISTIC STUDY OF RITUXIMAB AND BELIMUMAB COMBINATION THERAPY IN PR3 ANCA-ASSOCIATED VASCULITIS (COMBIVAS): STUDY PROTOCOL
8. 302. ALEMTUZUMAB FOR RELAPSING AND REFRACTORY PRIMARY SYSTEMIC VASCULITIS – A TRIAL OF EFFICACY AND SAFETY (ALEVIATE): A RANDOMISED OPEN-LABEL PHASE II CLINICAL TRIAL
9. 335. ALEMTUZUMAB FOR THE TREATMENT OF REFRACTORY BEHÇET’S DISEASE: A SUBGROUP ANALYSIS FROM A RANDOMIZED, PROSPECTIVE, OPEN LABEL, DOSE RANGING CLINICAL TRIAL (NCT01405807). A TRIAL OF EFFICACY AND SAFETY (ALEVIATE)
10. 176. THE COMPOSITION OF THE HUMAN NASAL MICROBIOME IN GRANULOMATOSIS WITH POLYANGIITIS: A PILOT STUDY
11. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis
12. Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models.
13. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis
14. novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis.
15. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.